



ABN 53 075 582 740

BIONOMICS LIMITED

ASX Results Announcement, Directors' Report and Financial Statements – 30 June 2015

Lodged with the ASX under Listing Rule 4.3A

Contents

Results for Announcement to the Market &
Supplementary Information 2

Announcement 3

Attachment - Directors' Report and Audited Financial
Statements

BIONOMICS LIMITED

Year ended 30 June 2015

(previous corresponding period: year ended 30 June 2014)

Results for Announcement to the Market

				\$
Cash and cash equivalents as at 30 June 2015				
from 30 June 2014	increased by	178%	to	26,558,006
Net operating and investing cash outflows for the period	increased by	137%	to	4,639,331
Revenue from ordinary activities	decreased by	65%	to	6,827,277
Revenue and other income	decreased by	40%	to	16,616,405
Loss from ordinary activities after tax attributable to members	decreased by	629%	to	16,949,405

NTA Backing

	<u>2015</u>	<u>2014</u>
Net tangible asset backing per ordinary share	4.4 cents	6.9 cents

Explanation of cash and cash equivalents position as at 30 June 2014:

The closing cash and cash equivalents position is in line with expectations and reflects the Company's continued investment in research and development. Upfront payments of US\$20 million from Merck & Co., Merck, were received in the September 2014 quarter and the company announced a US\$10 million debt financing through Silicon Valley Bank in November 2014 to develop BNC210.

Explanation of net movement in operating and investing cash outflows:

The net movement includes an increase in core R&D expenditure on the Company's clinical program BNC210, preparation of BNC101 cancer stem cell program for Phase 1 clinical trial in 2015 and the continued development of the product pipeline. Receipts from customers reflect the receipt of funds from Merck, contract services and sales of libraries by our wholly-owned subsidiary Prestwick Chemicals from 1 October 2014.

Explanation of revenue from ordinary activities:

Revenue consists of payments under Bionomics' 2014 agreement with Merck, contract service revenue of Bionomics' wholly-owned European subsidiaries Neurofit SAS and Prestwick, rental and interest income received as a result of ordinary activities and other income including the government's R&D Tax Incentive in Australia and similar incentives for the French subsidiaries.

Explanation of net profit from ordinary activities after tax:

The current year loss reflects the Company's investment in research and development activities. The Company's maiden profit in 2014 was a result of the licensing of the cognition program with Merck. For further detail, refer to the attached Directors' Report and audited Financial Statements.

Dividends/Distributions

Bionomics Limited does not propose to pay any dividend for the year ended 30 June 2015.



ABN 53 075 582 740

ASX ANNOUNCEMENT
10 August 2015

BIONOMICS REPORTS FULL YEAR FINANCIAL RESULTS

Adelaide, Australia: Bionomics Limited (ASX:BNO) (OTCQX:BNOEF) today announced its financial results for the 12 months to 30 June 2015.

Key Points – Financial

- Cash at 30 June 2015 was \$26,558,006, an increase of \$16,990,699 over the 30 June 2014 balance.
- Revenue and other income for the period was \$16,616,405, compared with \$27,545,996 for the period to 30 June 2014.
- The operating loss after tax of the Group for the period was \$16,949,405 and reflects the Company's continued execution of its business plan.

Corporate and R&D Highlights

Bionomics has continued the development of BNC210 which is now in a Phase 2 clinical trial of patients with Generalised Anxiety Disorder, or GAD, and we expect results in the third quarter of the 2016 calendar year. BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, or the $\alpha 7$ receptor. The Phase 2 trial is evaluating the capacity of BNC210 to engage brain systems relevant to anxiety using functional magnetic resonance imaging (fMRI). The endpoints of the trial include both significant changes in cerebral perfusion and in task-related brain activity using the emotional faces task. The clinical trial is being conducted at The Institute of Psychiatry, Psychology & Neuroscience at King's College in London.

In addition, a Phase 1 multiple ascending dose trial in which 54 healthy subjects are dosed twice daily for eight days is being conducted, with the primary endpoint of this clinical trial being safety and tolerability. We are measuring BNC210's effects on nicotine-induced EEG changes and expect results of the trial in the current quarter

Bionomics has continued to progress its lead cancer stem cell drug candidate BNC101 towards its first Phase 1 clinical trial in patients with metastatic colorectal cancer and metastatic pancreatic cancer. IND enabling studies and GMP manufacture are now complete and an IND application to the FDA is being finalised. Preclinical data supportive of the continued development of BNC101 was presented at several international scientific conferences including the 105th American Association for Cancer Research (AACR) and the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The data also included the preclinical activity of BNC101 in primary lung cancer and additional triple negative breast models.

The acquisition of Prestwick Chemical on 1 October 2014, enabled Bionomics to expand its MultiCore technology platform and European foothold with a premium medicinal chemistry services provider that also sells smart screening libraries to its bluechip customer base. This acquisition strengthens our global positioning and allows us to further identify and advance highly promising drug compounds for development and selective, strategic partnering.

Outlook

Bionomics is in a strong position to progress its development programs and continues to focus on its important relationship with Merck in pain and cognition to bring new treatments to patients suffering chronic and neuropathic pain and sufferers of memory loss associated with conditions such as ADHD, Alzheimer's Disease, Parkinson's disease and Schizophrenia.

We intend to advance the development of BNC210 to treat anxiety and depression. We have an ongoing Phase 2 clinical trial with BNC210 in 24 unmedicated generalised anxiety disorder patients and we expect results in the third quarter of the 2016 calendar year. BNC210 is being evaluated in a Phase 1 multiple ascending dose trial in which 54 healthy subjects are treated twice daily for eight days.

We also intend to advance the development of BNC101 to treat solid tumors by targeting cancer stem cells. We plan to initiate a Phase 1 clinical trial in patients with metastatic colorectal cancer and metastatic pancreatic cancer. This trial is expected to commence in the fourth quarter of the 2015 calendar year.

We will continue to progress our selective partnering strategy of programs within our robust pipeline.

FOR FURTHER INFORMATION PLEASE CONTACT:

DR DEBORAH RATHJEN
CEO & MANAGING DIRECTOR
BIONOMICS LIMITED
Ph: +61 8 8354 6101

MS MELANIE YOUNG
CFO
BIONOMICS LIMITED
Ph: +61 8 8354 6100

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumors. BNC101 is expected to enter a Phase 1 clinical trial in the fourth quarter of 2015. Bionomics also has strategic partnerships with Merck & Co. in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from

those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this report.